HEARTMATE 3™ LVAD DELIVERS UNPRECEDENTED* SURVIVAL AND SAFETY OUTCOMES AT 2 YEARS**,1
THE HIGHEST PUBLISHED 2-YEAR SURVIVAL RATE AND THE LOWEST PUBLISHED STROKE AND THROMBOSIS RATES FOR CONTINUOUS-FLOW LVADS1-5
HeartMate 3 LVAD outcomes made possible by Full MagLev™ Flow Technology.
HEARTMATE 3 LVAD MAKES A REAL DIFFERENCE IN PATIENT LIVES
Significant improvement in NYHA Class, 6-minute walk distance and quality of life1
More than 78% of patients improved to NYHA Class I/II from NYHA Class IIIb/IV by 6 months, with sustained improvement of 79% through two years.
SIGNIFICANT INCREASE IN 6-MINUTE WALK DISTANCE
At baseline, tested patients completed the 6-minute walk test at an average of 154 meters. At 2 years after HeartMate 3™ LVAD implant, patients completed the test at an average of 308 meters.1
MEANINGFUL IMPROVEMENT IN QUALITY OF LIFE1
Read the details of the clinical study as published in The New England Journal of Medicine.
BUILDING COMPREHENSIVE HEART FAILURE MANAGEMENT
The HeartMate 3™ LVAD is part of our heart failure management portfolio. Our vision is to transform the treatment of heart failure by designing technology that delivers excellent clinical outcomes and improves workflow and efficiency. Read more about our approach to heart failure management.
* Based on HeartMate™ LVAD highest published survival and lowest published stroke and thrombosis rates in continuous-flow LVAD category of devices in the U.S.1-5
** HeartMate 3™ LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.
1. Mehra MR, Goldstein DJ, Uriel N, et al. Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. N Engl J Med. 2018;378(15):1386-1395.
2. Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, ... Gregoric ID. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med. 2017;376(5):451-460.
3. Starling RC, Estep JD, Horstmanshof DA, et al; ROADMAP Study Investigators (2017). Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results. J Am Coll Cardio HF. 2017;5:518-27
4. Jorde, UP, Kushwaha SS, Tatooles AJ, et al. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS‡ registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardio. 2014;63:1751-7.
5. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-2251.